{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:56:32Z","timestamp":1774158992714,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100015756","name":"Janssen Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Region Centre Val de Loire"},{"name":"Labex SYNORG","award":["ANR-11-LABX-0029"],"award-info":[{"award-number":["ANR-11-LABX-0029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12859-016-1413-y","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T14:43:42Z","timestamp":1483627422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The use of novel selectivity metrics in kinase research"],"prefix":"10.1186","volume":"18","author":[{"given":"Nicolas","family":"Bosc","sequence":"first","affiliation":[]},{"given":"Christophe","family":"Meyer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-138X","authenticated-orcid":false,"given":"Pascal","family":"Bonnet","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"1413_CR2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912\u201334.","journal-title":"Science"},{"key":"1413_CR3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","volume":"10","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol. 2009;10:356\u201360.","journal-title":"Nat Immunol"},{"key":"1413_CR4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd3908","volume":"11","author":"M Guha","year":"2012","unstructured":"Guha M. Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov. 2012;11:892\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"1413_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.sbi.2006.01.013","volume":"16","author":"A Hopkins","year":"2006","unstructured":"Hopkins A, Mason J, Overington J. Can we rationally design promiscuous drugs? Curr Opin Struct Biol. 2006;16:127\u201336.","journal-title":"Curr Opin Struct Biol"},{"key":"1413_CR6","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"A Anighoro","year":"2014","unstructured":"Anighoro A, Bajorath J, Rastelli G. Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective. J Med Chem. 2014;57:7874\u201387.","journal-title":"J Med Chem"},{"key":"1413_CR7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","volume":"15","author":"S Giordano","year":"2008","unstructured":"Giordano S, Petrelli A. From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Curr Med Chem. 2008;15:422\u201332.","journal-title":"Curr Med Chem"},{"key":"1413_CR8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","volume":"10","author":"ZA Knight","year":"2010","unstructured":"Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10:130\u20137.","journal-title":"Nat Rev Cancer"},{"key":"1413_CR9","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1021\/jm8011036","volume":"51","author":"P Bamborough","year":"2008","unstructured":"Bamborough P, Drewry D, Harper G, Smith GK, Schneider K. Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. J Med Chem. 2008;51:7898\u2013914.","journal-title":"J Med Chem"},{"key":"1413_CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/0008-5472.379.65.2","volume":"65","author":"D Brehmer","year":"2005","unstructured":"Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res. 2005;65:379\u201382.","journal-title":"Cancer Res"},{"key":"1413_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature11127","volume":"486","author":"AC Dar","year":"2012","unstructured":"Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012;486:80\u20134.","journal-title":"Nature"},{"key":"1413_CR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/jm401138v","volume":"57","author":"T Saurat","year":"2014","unstructured":"Saurat T, Buron F, Rodrigues N, de Tauzia M-L, Colliandre L, Bourg S, et al. Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K\/mTOR Dual Inhibitors. J Med Chem. 2014;57:613\u201331.","journal-title":"J Med Chem"},{"key":"1413_CR13","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.2174\/0929867321666140414100127","volume":"21","author":"KD Tang","year":"2014","unstructured":"Tang KD, Ling M-T. Targeting Drug-Resistant Prostate Cancer with Dual PI3K\/mTOR Inhibition. Curr Med Chem. 2014;21:3048\u201356.","journal-title":"Curr Med Chem"},{"key":"1413_CR14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","volume":"3","author":"H Ma","year":"2008","unstructured":"Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discovery. 2008;3:607\u201321.","journal-title":"Expert Opin Drug Discovery"},{"key":"1413_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12154-009-0023-9","volume":"2","author":"LA Smyth","year":"2009","unstructured":"Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol. 2009;2:131\u201351.","journal-title":"J Chem Biol"},{"key":"1413_CR16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046\u201351.","journal-title":"Nat Biotechnol"},{"key":"1413_CR17","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1039\u201345.","journal-title":"Nat Biotechnol"},{"key":"1413_CR18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nchembio.530","volume":"7","author":"JT Metz","year":"2011","unstructured":"Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ. Navigating the kinome. Nat Chem Biol. 2011;7:200\u20132.","journal-title":"Nat Chem Biol"},{"key":"1413_CR19","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","volume":"104","author":"O Fedorov","year":"2007","unstructured":"Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, et al. A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases. Proc Natl Acad Sci. 2007;104:20523\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"1413_CR20","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1021\/jm070562u","volume":"50","author":"PP Graczyk","year":"2007","unstructured":"Graczyk PP. Gini Coefficient: A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases. J Med Chem. 2007;50:5773\u20139.","journal-title":"J Med Chem"},{"key":"1413_CR21","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1021\/jm100301x","volume":"53","author":"AC Cheng","year":"2010","unstructured":"Cheng AC, Eksterowicz J, Geuns-Meyer S, Sun Y. Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index. J Med Chem. 2010;53:4502\u201310.","journal-title":"J Med Chem"},{"key":"1413_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2105-12-94","volume":"12","author":"JC Uitdehaag","year":"2011","unstructured":"Uitdehaag JC, Zaman GJ. A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics. 2011;12:94.","journal-title":"BMC Bioinformatics"},{"key":"1413_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule\u2013kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329\u201336.","journal-title":"Nat Biotechnol"},{"key":"1413_CR24","doi-asserted-by":"crossref","first-page":"D191","DOI":"10.1093\/nar\/gku469","volume":"42","author":"The UniProt Consortium","year":"2014","unstructured":"The UniProt Consortium. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2014;42:D191\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1413_CR25","unstructured":"The IUPAC International Chemical Identifier (InChI) [Internet]. 2015. Available from: http:\/\/www.iupac.org\/home\/publications\/e-resources\/inchi.html . Accessed March 2015."},{"key":"1413_CR26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1039\/c003669b","volume":"6","author":"MK Hancock","year":"2010","unstructured":"Hancock MK, Lebakken CS, Wang J, Bi K. Multi-pathway cellular analysis of compound selectivity. Mol BioSyst. 2010;6:1834\u201343.","journal-title":"Mol BioSyst"},{"key":"1413_CR27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297\u2013315.","journal-title":"Biochem J"},{"key":"1413_CR28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813\u201323.","journal-title":"Nat Rev Cancer"},{"key":"1413_CR29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1471-2164-10-277","volume":"10","author":"UT Shankavaram","year":"2009","unstructured":"Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. Cell Miner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 2009;10:277.","journal-title":"BMC Genomics"},{"key":"1413_CR30","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. Cell Miner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res. 2012;72:3499\u2013511.","journal-title":"Cancer Res"},{"key":"1413_CR31","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1073\/pnas.0502000102","volume":"102","author":"JG Conway","year":"2005","unstructured":"Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci. 2005;102:16078\u201383.","journal-title":"Proc Natl Acad Sci"},{"key":"1413_CR32","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","volume":"18","author":"SD Barrett","year":"2008","unstructured":"Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008;18:6501\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"1413_CR33","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","volume":"12","author":"T Hideshima","year":"2006","unstructured":"Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, et al. MLN120B, a Novel I B Kinase Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clin Cancer Res. 2006;12:5887\u201394.","journal-title":"Clin Cancer Res"},{"key":"1413_CR34","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1158\/1535-7163.MCT-09-0477","volume":"8","author":"SG Buchanan","year":"2009","unstructured":"Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud P-Y, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009;8:3181\u201390.","journal-title":"Mol Cancer Ther"},{"key":"1413_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","volume":"26","author":"EI Heath","year":"2008","unstructured":"Heath EI, Bible K, Martell RE, Adelman DC, LoRusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investig New Drugs. 2008;26:59\u201365.","journal-title":"Investig New Drugs"},{"key":"1413_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowanjacob S, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129\u201341.","journal-title":"Cancer Cell"},{"key":"1413_CR37","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-10-0095","volume":"9","author":"Y Degenhardt","year":"2010","unstructured":"Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, et al. Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability. Mol Cancer Ther. 2010;9:2079\u201389.","journal-title":"Mol Cancer Ther"},{"key":"1413_CR38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/ml2001455","volume":"2","author":"JP Duffy","year":"2011","unstructured":"Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, et al. The Discovery of VX-745: A Novel and Selective p38\u03b1 Kinase Inhibitor. ACS Med Chem Lett. 2011;2:758\u201363.","journal-title":"ACS Med Chem Lett"},{"key":"1413_CR39","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood"},{"key":"1413_CR40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.22576","volume":"55","author":"EA Kolb","year":"2010","unstructured":"Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:668\u201377.","journal-title":"Pediatr Blood Cancer"},{"key":"1413_CR41","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic\/Pharmacodynamic Relationship. Clin Cancer Res. 2003;9:327\u201337.","journal-title":"Clin Cancer Res"},{"key":"1413_CR42","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1158\/1535-7163.MCT-13-0084","volume":"12","author":"A-M Ellegaard","year":"2013","unstructured":"Ellegaard A-M, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J, et al. Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance. Mol Cancer Ther. 2013;12:2018\u201330.","journal-title":"Mol Cancer Ther"},{"key":"1413_CR43","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1016\/S0021-9258(18)98335-3","volume":"268","author":"G Martiny-Baron","year":"1993","unstructured":"Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole G\u00f6 6976. J Biol Chem. 1993;268:9194\u20137.","journal-title":"J Biol Chem"},{"key":"1413_CR44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0006-291X(03)01318-4","volume":"308","author":"NV Jammi","year":"2003","unstructured":"Jammi NV, Whitby LR, Beal PA. Small molecule inhibitors of the RNA-dependent protein kinase. Biochem Biophys Res Commun. 2003;308:50\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1413_CR45","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1021\/jm060216x","volume":"49","author":"DJ Pratt","year":"2006","unstructured":"Pratt DJ, Bentley J, Jewsbury P, Boyle FT, Endicott JA, Noble MEM. Dissecting the Determinants of Cyclin-Dependent Kinase 2 and Cyclin-Dependent Kinase 4 Inhibitor Selectivity \u2020. J Med Chem. 2006;49:5470\u20137.","journal-title":"J Med Chem"},{"key":"1413_CR46","first-page":"566","volume":"60","author":"JR Jackson","year":"2000","unstructured":"Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An Indolocarbazole Inhibitor of Human Checkpoint Kinase (Chk1) Abrogates Cell Cycle Arrest Caused by DNA Damage. Cancer Res. 2000;60:566\u201372.","journal-title":"Cancer Res"},{"key":"1413_CR47","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuroscience.2006.12.019","volume":"145","author":"MA Carrasco","year":"2007","unstructured":"Carrasco MA, Castro P, Sepulveda FJ, Tapia JC, Gatica K, Davis MI, et al. Regulation of glycinergic and GABAergic synaptogenesis by brain-derived neurotrophic factor in developing spinal neurons. Neuroscience. 2007;145:484\u201394.","journal-title":"Neuroscience"},{"key":"1413_CR48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-suppl_3-10","volume":"9","author":"HA Burris","year":"2004","unstructured":"Burris HA. Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR\/ErbB-2 Inhibitor Lapatinib. Oncologist. 2004;9:10\u20135.","journal-title":"Oncologist"},{"key":"1413_CR49","first-page":"777","volume":"1","author":"SSW Ng","year":"2002","unstructured":"Ng SSW, Tsao M-S, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1:777\u201383.","journal-title":"Mol Cancer Ther"},{"key":"1413_CR50","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/0008-5472.CAN-04-2484","volume":"65","author":"JM Golas","year":"2005","unstructured":"Golas JM. SKI-606, a Src\/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models. Cancer Res. 2005;65:5358\u201364.","journal-title":"Cancer Res"},{"key":"1413_CR51","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","volume":"104","author":"AS Corbin","year":"2004","unstructured":"Corbin AS. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004;104:3754\u20137.","journal-title":"Blood"},{"key":"1413_CR52","first-page":"29","volume":"14","author":"M Baranc\u00edk","year":"2001","unstructured":"Baranc\u00edk M, Boh\u00e1cov\u00e1 V, Kvackajov\u00e1 J, Hudecov\u00e1 S, Krizanov\u00e1 O, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2001;14:29\u201336.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"1413_CR53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493\u2013502.","journal-title":"Nat Rev Drug Discov"},{"key":"1413_CR54","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"KA Hahn","year":"2008","unstructured":"Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. J Vet Intern Med. 2008;22:1301\u20139.","journal-title":"J Vet Intern Med"},{"key":"1413_CR55","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Res. 2005;65:4500\u20135.","journal-title":"Cancer Res"},{"key":"1413_CR56","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.24926","volume":"126","author":"M L\u00f3pez-Fauqued","year":"2010","unstructured":"L\u00f3pez-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Molin\u00e9 T, et al. The dual PI3K\/mTOR inhibitor PI-103 promotes immunosupression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 2010;126:1549\u201361.","journal-title":"Int J Cancer"},{"key":"1413_CR57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nbt.2021","volume":"29","author":"C Zhang","year":"2011","unstructured":"Zhang C, Habets G, Bollag G. Interrogating the kinome. Nat Biotechnol. 2011;29:981\u20133.","journal-title":"Nat Biotechnol"},{"key":"1413_CR58","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.drudis.2015.01.002","volume":"20","author":"E Jacoby","year":"2015","unstructured":"Jacoby E, Tresadern G, Bembenek S, Wroblowski B, Buyck C, Neefs J-M, et al. Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today. 2015;20:652\u20138.","journal-title":"Drug Discov Today"},{"key":"1413_CR59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM, Santoro A. Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma. Drugs. 2009;69:223\u201340.","journal-title":"Drugs"},{"key":"1413_CR60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clin Cancer Res. 2011;17:989\u20131000.","journal-title":"Clin Cancer Res"},{"key":"1413_CR61","first-page":"23","volume":"39","author":"T Sakai","year":"2011","unstructured":"Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39:23\u201331.","journal-title":"Int J Oncol"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T15:46:41Z","timestamp":1718984801000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-016-1413-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1186\/s12859-016-1413-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]},"article-number":"17"}}